Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
Baxter
Dow
Boehringer Ingelheim

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR PEMETREXED


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Pemetrexed

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003711 ↗ Combination Chemotherapy in Treating Patients With Metastatic Solid Tumors Completed San Antonio Cancer Institute Phase 1 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with pemetrexed disodium and irinotecan in treating patients who have metastatic solid tumors.
NCT00005636 ↗ Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed National Cancer Institute (NCI) Phase 3 1999-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
NCT00005636 ↗ Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed Memorial Sloan Kettering Cancer Center Phase 3 1999-11-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
NCT00006007 ↗ LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 2000-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metastatic breast cancer.
NCT00006007 ↗ LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer Completed Alliance for Clinical Trials in Oncology Phase 2 2000-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metastatic breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pemetrexed

Condition Name

Condition Name for Pemetrexed
Intervention Trials
Non-small Cell Lung Cancer 135
Lung Cancer 75
Non Small Cell Lung Cancer 70
Carcinoma, Non-Small-Cell Lung 55
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pemetrexed
Intervention Trials
Carcinoma, Non-Small-Cell Lung 540
Lung Neoplasms 505
Mesothelioma 94
Mesothelioma, Malignant 89
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pemetrexed

Trials by Country

Trials by Country for Pemetrexed
Location Trials
China 445
Italy 357
Spain 325
Taiwan 94
Poland 93
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pemetrexed
Location Trials
California 183
New York 166
Texas 164
Florida 157
Pennsylvania 154
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pemetrexed

Clinical Trial Phase

Clinical Trial Phase for Pemetrexed
Clinical Trial Phase Trials
Phase 4 16
Phase 3 157
Phase 2/Phase 3 17
[disabled in preview] 528
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pemetrexed
Clinical Trial Phase Trials
Completed 354
Recruiting 164
Terminated 104
[disabled in preview] 159
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pemetrexed

Sponsor Name

Sponsor Name for Pemetrexed
Sponsor Trials
Eli Lilly and Company 167
National Cancer Institute (NCI) 105
Merck Sharp & Dohme Corp. 47
[disabled in preview] 67
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pemetrexed
Sponsor Trials
Other 718
Industry 605
NIH 105
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Colorcon
Mallinckrodt
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.